Recursion Pharmaceuticals, Inc.
RXRXNext catalyst
REC-4881
AXIN1 Gene Mutation
Get an email about RXRX's next catalysts
Track Recursion Pharmaceuticals (RXRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
3 upcoming, 2 past
Data Readout — REC-4881
Recursion maintains 'Hold' rating with REC-4881 program update expected by end of 2026 and collaboration candidates in development.
REC-4881 Phase 2: after 12 weeks, nearly 1 in 2 upper GI patients and >1 in 3 lower GI patients achieved >=65% polyp burden reduction; 85% of evaluable patients remained below baseline 12 weeks off treatment; no new safety signals. REC-1245 Phase 1: 2 confirmed partial responses in endometrial cancer, 1 unconfirmed PR in liver cancer, 91.7% disease control rate (11/12) at doses >=45 mg; 45 mg chosen for expansion cohort. Sanofi also exercised option on first development candidate (oral dual-targeting small molecule in immunology), Phase 1 expected to start in 2027.
SourceREC-4881 Phase 2 Est. Readout
Primary completion for REC-4881 trial (NCT06005974) in AXIN1 Gene Mutation
After 12 weeks of treatment, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction; approximately one in three patients achieved reductions of ≥65%.
SourceREC-4881 Phase 2 Est. Readout (TUPELO)
Primary completion for REC-4881 trial (NCT05552755) in Familial Adenomatous Polyposis
SourceMarket Overview
Stock performance and key metrics
Frequently asked questions
What is in Recursion Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Recursion Pharmaceuticals, Inc.'s (RXRX) pipeline across Phase 2. Its lead program is REC-4881 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Recursion Pharmaceuticals, Inc.'s next FDA catalyst?→
Recursion Pharmaceuticals, Inc.'s (RXRX) next tracked catalyst is a Phase 2 readout expected June 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RXRX biotech catalysts?→
Add RXRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Recursion Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.